药明康德(603259.SH):药明基金一期拟认购D3 Bio2100万股A-1批次优先股
格隆汇11月17日丨药明康德(603259.SH)公布,公司全资子企业WuXi Pharma TechHealthcare Fund I L.P.(以下简称“药明基金一期”)拟认购D3 Bio, Inc.(以下简称“D3 Bio”)新发行的2100万股A-1批次优先股股份,认购价格为1美元/股,金额合计2100万美元,交易完成后持有D3 Bio的股权比例约为16.67%(全面摊薄和转换基础上)。
D3 Bio是一家初创的生物制药企业,目前尚无任何药物可用于商业化销售。D3 Bio的大多数在研产品均处于临床前阶段,其业务未来能否成功取决于这些在研产品的研发结果。作为一家初创生物制药企业,D3 Bio的业务失败风险较高,如果其研发业务失败,公司可能无法收回投资。
D3 Bio目前尚未取得任何收入,且其未来能否产生收入取决于其在研产品是否能够完成临床试验、获得监管批准并成功商业化等因素。若D3 Bio所研发的产品未能成功商业化,其可能无法创收并盈利。
D3 Bio进行药品研发需要大量长期的资本投入,且其能否成功取决于未来的临床试验和监管审批结果以及其他竞争性产品的研发和上市进程,因此对于D3 Bio的投资具有较高不确定性。如果D3 Bio本轮融资因先决条件未能满足而无法完成或其后续无法获得进一步融资,可能会对其业务产生重大不利影响,并导致公司的投资失败。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.